Amneal Pharmaceuticals, Inc. Class A Common Stock (NASDAQ:AMRX) — Stock Price

$17.88 USD
▼ -1.43% today

Amneal Pharmaceuticals, Inc. Class A Common Stock (NASDAQ:AMRX) is currently trading at $17.88 USD, down 1.43% today. Over the past 52 weeks, shares have ranged between $11.81 and $19.10. This page tracks Amneal Pharmaceuticals, Inc. Class A Common Stock's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Amneal Pharmaceuticals, Inc. Class A Com (AMRX) total market value.

Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Amneal Pharmaceuticals, Inc. Class A Common Stock's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.

Amneal Pharmaceuticals, Inc. Class A Common Stock Income Statement — Revenue, Profit & Earnings by Year

Amneal Pharmaceuticals, Inc. Class A Common Stock's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue $3.02 Billion $2.79 Billion $2.39 Billion $2.21 Billion $2.09 Billion
Cost of Revenue $1.88 Billion $1.77 Billion $1.53 Billion $1.42 Billion $1.32 Billion
Gross Profit $1.14 Billion $1.02 Billion $863.87 Million $791.46 Million $768.97 Million
Research & Development $186.18 Million $190.71 Million $194.75 Million $208.66 Million $209.56 Million
SG&A $526.83 Million $442.04 Million $417.27 Million $382.90 Million $365.70 Million
Total Operating Expenses $713.00 Million $771.11 Million $659.50 Million $886.39 Million $616.26 Million
Operating Income $423.09 Million $249.33 Million $204.37 Million $-94.93 Million $152.72 Million
EBITDA $603.87 Million $439.77 Million $500.78 Million $440.21 Million $401.10 Million
EBIT $380.30 Million $203.58 Million $271.38 Million $200.03 Million $167.69 Million
Interest Expense $241.09 Million $258.60 Million $210.63 Million $158.38 Million $136.32 Million
Income Before Tax $139.21 Million $-55.01 Million $-40.27 Million $-248.13 Million $31.37 Million
Income Tax Expense $11.28 Million $18.86 Million $8.45 Million $6.66 Million $11.20 Million
Net Income $72.06 Million $-116.89 Million $-83.99 Million $-129.99 Million $10.62 Million

Amneal Pharmaceuticals, Inc. Class A Common Stock Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Amneal Pharmaceuticals, Inc. Class A Common Stock's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets $3.68 Billion $3.50 Billion $3.47 Billion $3.80 Billion $3.94 Billion
Total Current Assets $1.91 Billion $1.59 Billion $1.38 Billion $1.41 Billion $1.52 Billion
Cash & Equivalents — — — — —
Short-term Investments — $1.87 Million $2.20 Million $1.82 Million $1.17 Million
Net Receivables $939.87 Million $775.73 Million $645.66 Million $741.79 Million $694.74 Million
Inventory $606.30 Million $612.45 Million $581.38 Million $530.74 Million $489.39 Million
Property, Plant & Equipment — — — $469.81 Million $514.16 Million
Goodwill $595.47 Million $597.44 Million $598.63 Million $598.85 Million $593.02 Million
Total Liabilities $3.67 Billion $3.55 Billion $3.41 Billion $3.59 Billion $3.57 Billion
Total Current Liabilities $881.63 Million $1.13 Billion $846.60 Million $752.80 Million $677.24 Million
Long-term Debt $2.57 Billion $2.16 Billion $2.43 Billion $2.59 Billion $2.68 Billion
Net Debt $2.43 Billion $2.48 Billion $2.66 Billion $2.82 Billion $2.63 Billion
Total Stockholder Equity $-70.79 Million $-109.27 Million $19.78 Million $298.42 Million $360.34 Million
Retained Earnings $-535.00 Million $-607.06 Million $-490.18 Million $-406.18 Million $-276.20 Million

Amneal Pharmaceuticals, Inc. Class A Common Stock Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Amneal Pharmaceuticals, Inc. Class A Common Stock generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow $339.99 Million $295.10 Million $345.58 Million $65.10 Million $241.82 Million
Capital Expenditures $70.06 Million $74.99 Million $69.19 Million $90.59 Million $47.73 Million
Free Cash Flow $269.93 Million $220.11 Million $276.39 Million $-25.50 Million $194.09 Million
Investing Cash Flow $-112.26 Million $-63.00 Million $-69.19 Million $-174.31 Million $-194.18 Million
Financing Cash Flow $-31.53 Million $-211.79 Million $-212.57 Million $-106.62 Million $-138.12 Million
Dividends Paid — — — $3.57 Million —
Stock-Based Compensation $31.95 Million $27.77 Million $26.82 Million $31.85 Million $28.41 Million
Depreciation $223.57 Million $236.19 Million $229.40 Million $240.18 Million $233.41 Million
Change in Cash $194.52 Million $19.31 Million $63.88 Million $-221.51 Million $-90.38 Million

Amneal Pharmaceuticals, Inc. Class A Common Stock Earnings History — EPS Actual vs. Analyst Estimates

Track Amneal Pharmaceuticals, Inc. Class A Common Stock's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Aug 04, 2026 — 0.23 —
May 01, 2026 0.27 0.19 +38.96%
Feb 27, 2026 0.21 0.18 +16.67%
Oct 30, 2025 0.17 0.14 +21.43%
Aug 05, 2025 0.25 0.17 +47.06%
May 02, 2025 0.21 0.15 +40.00%
Feb 28, 2025 0.12 0.15 -20.00%
Nov 08, 2024 0.16 0.14 +14.29%